10-Q: Oragenics Faces Financial Hurdles, Delays in ONP-002 Trial

Oragenics reports increased R&D spending and significant net losses, while facing device stability issues and a pause in its ONP-002 clinical trial, alongside ongoing NYSE American listing concerns.

Summary

• Oragenics reported a net loss of $2.6 million for the three months ended September 30, 2026, and $7.3 million for the nine months ended September 30, 2026.
• Research and development expenses increased significantly, up 69.3% for the quarter and 97.3% for the nine-month period, primarily related to the ONP-002 program.
• General and administrative expenses decreased by 53.5% for the quarter and 21.3% for the nine-month period.
• The company encountered device stability concerns with its ONP-002 program in September 2026, leading to a pause in participant enrollment and potential delays in IND application submission.
• Oragenics received a notice from NYSE American regarding non-compliance with continued listing standards but has been granted a plan period through February 25, 2028, to regain compliance.
• The company has substantial doubt about its ability to continue as a going concern, with current working capital expected to fund operations only through December 31, 2026.
• Cash and cash equivalents stood at $2.2 million as of September 30, 2026, a decrease from $4.4 million at December 31, 2025.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative sentiment due to significant financial challenges, ongoing concerns about continuing as a going concern, and potential delisting from the NYSE American.

Positives

• Research and development expenses increased significantly, indicating continued investment in the ONP-002 program.
• General and administrative expenses saw a substantial decrease, improving operational efficiency.
• Zero serious adverse events have been reported in the Phase IIa clinical trial for ONP-002.
• The company has been granted a plan period through February 25, 2028, by the NYSE American to regain compliance with listing standards.

Negatives

• Significant net losses continue, with a $2.6 million loss for the quarter and $7.3 million for the nine months.
• Cash and cash equivalents decreased to $2.2 million as of September 30, 2026, raising concerns about liquidity.
• Device stability concerns in the ONP-002 program have caused a pause in enrollment and potential delays.
• The company faces substantial doubt regarding its ability to continue as a going concern.
• The company received a notice of non-compliance with NYSE American continued listing standards.

Risks

• The company cannot assure that it will regain compliance with NYSE American listing standards by February 25, 2028, which could lead to delisting.
• The device stability concerns with ONP-002 could significantly delay the IND application submission and subsequent clinical trials.
• The company's ability to continue as a going concern is in substantial doubt due to recurring losses, accumulated deficit, and negative cash flows.
• Failure to raise sufficient capital could force the company to delay, reduce, or abandon its research and development programs and future commercialization efforts.
• The anti-dilution provisions in the Series H Preferred Stock could lead to an indeterminate number of shares being issued upon conversion, causing significant dilution.
• The market price of common stock may never exceed the conversion price of Series H Preferred Stock, potentially leading to unexercised warrants and a need for earlier capital raises.

Future Outlook

The company expects to continue incurring substantial expenditures to advance the ONP-002 program and explore strategic opportunities. However, this is contingent on raising additional capital, for which there are no assurances. Current working capital is expected to fund operations through December 31, 2026. Future capital requirements will depend on R&D success, clinical trial progress, and the ability to secure partnerships or financing.

Management Comments

• "Subject to our ability to raise additional capital, of which there can be no assurances, we expect to continue to incur substantial expenses as we attempt to advance the development of ONP-002, our lead product candidate for the treatment of mild traumatic brain injury and explore potential acquisitions."
• "We believe our current working capital will be sufficient to fund planned operations through December 31, 2026, depending on the timing and scope of our development activities and other strategic decisions."
• "There can be no assurance that we will be able to obtain such financing on acceptable terms, or at all. If we are unable to raise sufficient capital in the future, we may be forced to delay, reduce, or abandon our research and development programs and future acquisition and commercialization efforts, which would adversely affect our business prospects and ability to continue as a going concern."

Industry Context

StockSavvy.ai notes that Oragenics operates in the highly competitive and capital-intensive biopharmaceutical sector, where success is heavily reliant on clinical trial outcomes, regulatory approvals, and continuous funding. The company's focus on ONP-002 for mild traumatic brain injury addresses a significant unmet medical need, but the path to commercialization is fraught with challenges, including lengthy development timelines and substantial R&D costs.

Comparison to Industry Standards

• The net loss of $7.3 million for the nine months ended September 30, 2026, is substantial for a development-stage company, but not uncommon in the biopharmaceutical industry where significant investment is required before revenue generation.
• The increase in R&D expenses (97.3% year-over-year for nine months) aligns with industry practice for companies advancing drug candidates through clinical trials.
• The company's cash burn rate of approximately $6.4 million for the nine-month period is a critical metric. Companies in this space often require multiple financing rounds to reach commercialization, and a burn rate of this magnitude necessitates consistent access to capital.
• The ongoing struggle to meet NYSE American listing requirements due to low stockholders' equity is a common challenge for development-stage biotechs that have not yet achieved profitability or significant revenue.

Legal Proceedings

• Jacob Vanlandingham filed a Complaint for a Pure Bill of Discovery on April 24, 2026, seeking discovery related to the company's purchase of assets from Odyssey in December 2023. The company believes the complaint is without merit and intends to contest it.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances and the anti-dilution provisions of Series H Preferred Stock.
• Shareholders also face the risk of delisting from the NYSE American if compliance standards are not met.
• Creditors and suppliers may face increased risk due to the company's going concern status and liquidity challenges.

Next Steps

• Continue to evaluate device stability concerns for ONP-002.
• Pursue FDA guidance on the planned U.S. clinical development program for ONP-002.
• Explore financing alternatives and strategic business development opportunities.
• Work towards regaining compliance with NYSE American continued listing standards by February 25, 2028.
• Continue to advance the ONP-002 program, subject to capital availability.

Key Dates

Recommendation

The company is facing significant financial distress, including substantial net losses, dwindling cash reserves, and a going concern warning. The delay in its lead product candidate's clinical trials due to device stability issues, coupled with the ongoing threat of delisting from the NYSE American, presents a high-risk investment profile. Without a clear path to substantial capital infusion or a resolution to the technical and financial challenges, the outlook for existing shareholders is negative.

Keywords

ONP-002, mild traumatic brain injury, concussion, clinical trials, biopharmaceutical, going concern, NYSE American, R&D expenses